Scinai Immunotherapeutics Ltd (SCNI NASDAQ) stock market data APIs
$2.73
-0.02(-0.7%)
as of May 30, 2025
Try our APIs with
free plan!
Scinai Immunotherapeutics Ltd Financial Data Overview
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications, such as plaque psoriasis, psoriatic arthritis, asthma, and wet macular degeneration. It also develops PC111, a monoclonal antibody in development for treating Pemphigus, Steven Johnson's Syndrome and Toxic Epidermal Necrolysis. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Prev. Close
2.73
Open
2.7098
High
2.8485
Low
2.7098
52 wk Range
1.9-6.97
Market Cap
2 720 K
P/E Ratio
0
Shares Outstanding
1 000 K
Revenue
658 K
EPS
-2.6351
Beta
2.23
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Scinai Immunotherapeutics Ltd data using free add-ons & libraries
Get Scinai Immunotherapeutics Ltd Fundamental Data
Scinai Immunotherapeutics Ltd Fundamental data includes:
- Net Revenue: 658 K
- EBITDA: -6 989 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-26
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Scinai Immunotherapeutics Ltd News
New
Scinai Immunotherapeutics reports Q1 results
* Scinai Immunotherapeutics press release [https://seekingalpha.com/pr/20121077-scinai-reports-q1-2025-financial-results-highlighting-strong-cdmo-revenue-momentum-and] (NASDAQ:SCNI [https://seekinga...
7 F-Rated Stocks for Your August 2024 Sell List
There’s nothing wrong with trying to get in early on a stock. Some of your best winners will be companies you identify before the rest of the pack – that’s why investors spend a lot of time rese...
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
JERUSALEM, Nov. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that the Israel Innovation Authority (IIA) has approved a non-dilutive grant cov...
Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
JERUSALEM, Nov. 03, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovati...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
